[8-K] Medical Properties Trust, Inc. Reports Material Event

Rhea-AI Filing Summary

SpartanNash (SPTN) filed an 8-K to furnish a Regulation FD press release. The Company will release fiscal Q2-25 results before market open on 14 Aug 2025 but, because of its pending sale to C&S Wholesale Grocers, no earnings conference call will be held.

The filing reiterates that the all-cash acquisition, originally announced 23 Jun 2025, is expected to close in late 2025 subject to customary conditions, including shareholder and regulatory approvals. A definitive proxy statement was filed and mailed on 31 Jul 2025; investors are urged to review it before voting.

The Company disclaims that the furnished information is not deemed “filed” for Exchange Act purposes and cautions about forward-looking statements, highlighting risks such as shareholder vote failure, regulatory hurdles, litigation, financing availability and potential workforce or customer disruption. Exhibits include the press release (Ex. 99.1) and iXBRL cover page data (Ex. 104).

Insights

M&A Specialist

TL;DR: Filing signals acquisition process is on track; lack of call reduces visibility.

SpartanNash’s decision to forego the customary Q2 earnings call underscores management’s focus on completing the C&S buy-out. The proxy is already mailed, indicating the timeline is progressing as planned. While no new deal terms are provided, reconfirming a late-2025 close reassures investors the transaction has not stalled. However, the absence of live Q&A eliminates an information source that could clarify interim performance or integration planning, creating a near-term transparency gap. Overall, the disclosure is routine and neutral to valuation until additional regulatory or voting milestones are cleared.

Sell-Side Equity Analyst

TL;DR: Operational insight deferred; headline risk unchanged.

The 8-K offers no financial metrics, merely scheduling the 14 Aug print. Investors expecting color on margins, inflation pass-through or supply-chain costs will be disappointed. Nevertheless, the reiteration of deal timing and proxy mailing suggests low execution risk. Given that the agreed transaction price effectively caps upside, share movement will likely track deal-spread dynamics and regulatory commentary rather than fundamentals. I view today’s filing as non-impactful to the deal arb case.

MEDICAL PROPERTIES TRUST INC false 0001287865 0001287865 2025-07-31 2025-07-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 31, 2025

MEDICAL PROPERTIES TRUST, INC.

(Exact Name of Registrant as Specified in Charter)

Commission File Number 001-32559

Maryland		20-0191742
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1000 Urban Center Drive, Suite 501 Birmingham, AL		35242
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code

(205) 969-3755

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc.		MPW		The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On July 31, 2025, Medical Properties Trust, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference in any filing of Medical Properties Trust, Inc. with the Securities and Exchange Commission, except as expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press release dated July 31, 2025 reporting financial results for the three and six months ended June 30, 2025
99.2		Medical Properties Trust, Inc. 2nd Quarter 2025 Supplemental Information
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.

MEDICAL PROPERTIES TRUST, INC.
By:		/s/ R. Steven Hamner
Name:		R. Steven Hamner
Title:		Executive Vice President and Chief Financial Officer

Date: July 31, 2025

3